The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial.
 
Darren R. Feldman
Research Funding - Novartis; Seagen
 
Chung-Han Lee
Consulting or Advisory Role - Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Pfizer (Inst)
 
Ana M. Molina
Honoraria - ASCO
Consulting or Advisory Role - Eisai; Exelixis; Novartis
 
Andrea Knezevic
No Relationships to Disclose
 
Yingbei Chen
No Relationships to Disclose
 
Joshua Chaim
No Relationships to Disclose
 
Devyn Taylor Coskey
Research Funding - Novartis
 
Yasser Ged
No Relationships to Disclose
 
Satish Tickoo
No Relationships to Disclose
 
Victor E. Reuter
No Relationships to Disclose
 
Sujata Patil
No Relationships to Disclose
 
Han Xiao
No Relationships to Disclose
 
Jahan Aghalar
No Relationships to Disclose
 
Arlyn J. Apollo
No Relationships to Disclose
 
Maria Isabel Carlo
No Relationships to Disclose
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Exelixis; GlaxoSmithKline; Natera; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Travel, Accommodations, Expenses - Novartis; Takeda